Search
Aytu Biopharma Inc
AYTUAdd to Watchlist
1.900USD
-0.030-1.55%
Close 10-27 16:00（ET）
20.65MMarket Cap
LossP/E TTM
Aytu Biopharma Inc (AYTU) Stock Price Target & Forecast
Analyst Rating
Based on 3 analysts giving stock ratings to Aytu Biopharma Inc in the past month.
Buy
0 Strong Buy
3 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
9.667USD+400.86%
AYTU Analyst Recommendation Trends
In the current month, AYTU has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AYTU average Analyst price target in the last month is 9.667.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
0
0
0
0
0
0
0
0
3
3
3
3
3
3
3
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
3
3
3
3
3
3
3
AYTU Analyst Rating for Peer Comparison
Updated: Oct 27, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
9
17
11
1
0
38
Amgen Inc
AMGN
4
9
19
3
1
36
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Eli Lilly and Co
LLY
10
19
3
1
0
33
Alnylam Pharmaceuticals Inc
ALNY
7
17
8
0
0
32
AbbVie Inc
ABBV
8
18
6
0
0
32
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Merck & Co Inc
MRK
7
16
8
0
0
31
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Bristol-Myers Squibb Co
BMY
5
6
18
1
0
30
Financial Forecasting
Based on analysts' estimates, AYTU EPS is projected to reach -0.335 in FY2027Q1, following reported EPS of -0.001 in FY2026Q4. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
FY2027Q2
Forecast
-0.60
-0.51
-0.33
-0.34
-0.26
Actual
-1.05
-0.53
-0.00
--
--
Surprise
-75.76%
-4.80%
+99.62%
--
--
FAQs
What is Aytu Biopharma Inc's expected revenue for the next quarter?
Aytu Biopharma Inc's expected revenue is 13.27M.
What is Aytu Biopharma Inc's price target?
Analysts forecast that Aytu Biopharma Inc's price target is USD 9.67, with the highest forecast at USD 15.00 and the lowest forecast at USD 7.00.
How have Aytu Biopharma IncAYTU's recent earnings per share performed?
The market expectation was USD -0.00, while Aytu Biopharma IncAYTU's earnings per share (EPS) for the previous quarter was USD -0.53. EPS for the next quarter is expected at USD -0.34.
What is the analyst rating for Aytu Biopharma Inc?
Based on the ratings of Aytu Biopharma Inc's stock from 3 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.